|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTSS1L |
Gene summary for MTSS1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTSS1L | Gene ID | 92154 |
| Gene name | MTSS I-BAR domain containing 2 | |
| Gene Alias | ABBA | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0007009 | UniProtAcc | Q765P7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 92154 | MTSS1L | P31T-E | Human | Esophagus | ESCC | 2.04e-17 | 2.69e-01 | 0.1251 |
| 92154 | MTSS1L | P32T-E | Human | Esophagus | ESCC | 6.45e-07 | 1.11e-01 | 0.1666 |
| 92154 | MTSS1L | P37T-E | Human | Esophagus | ESCC | 6.23e-05 | 1.73e-01 | 0.1371 |
| 92154 | MTSS1L | P38T-E | Human | Esophagus | ESCC | 2.83e-02 | 1.10e-01 | 0.127 |
| 92154 | MTSS1L | P39T-E | Human | Esophagus | ESCC | 2.66e-05 | 6.74e-02 | 0.0894 |
| 92154 | MTSS1L | P42T-E | Human | Esophagus | ESCC | 2.04e-05 | 1.58e-01 | 0.1175 |
| 92154 | MTSS1L | P44T-E | Human | Esophagus | ESCC | 9.95e-03 | 1.29e-01 | 0.1096 |
| 92154 | MTSS1L | P47T-E | Human | Esophagus | ESCC | 2.08e-08 | 1.20e-01 | 0.1067 |
| 92154 | MTSS1L | P48T-E | Human | Esophagus | ESCC | 8.35e-07 | 1.40e-01 | 0.0959 |
| 92154 | MTSS1L | P52T-E | Human | Esophagus | ESCC | 4.33e-05 | 9.17e-02 | 0.1555 |
| 92154 | MTSS1L | P54T-E | Human | Esophagus | ESCC | 1.10e-04 | 2.20e-01 | 0.0975 |
| 92154 | MTSS1L | P57T-E | Human | Esophagus | ESCC | 1.19e-04 | 1.36e-01 | 0.0926 |
| 92154 | MTSS1L | P61T-E | Human | Esophagus | ESCC | 5.54e-06 | 1.37e-01 | 0.099 |
| 92154 | MTSS1L | P62T-E | Human | Esophagus | ESCC | 2.98e-11 | 1.46e-01 | 0.1302 |
| 92154 | MTSS1L | P65T-E | Human | Esophagus | ESCC | 5.27e-06 | 1.34e-01 | 0.0978 |
| 92154 | MTSS1L | P74T-E | Human | Esophagus | ESCC | 3.38e-04 | 9.36e-02 | 0.1479 |
| 92154 | MTSS1L | P75T-E | Human | Esophagus | ESCC | 1.17e-12 | 2.21e-01 | 0.1125 |
| 92154 | MTSS1L | P76T-E | Human | Esophagus | ESCC | 1.03e-08 | 1.16e-01 | 0.1207 |
| 92154 | MTSS1L | P79T-E | Human | Esophagus | ESCC | 1.73e-12 | 2.38e-01 | 0.1154 |
| 92154 | MTSS1L | P80T-E | Human | Esophagus | ESCC | 2.71e-08 | 2.36e-01 | 0.155 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTSS1L | SNV | Missense_Mutation | c.1090N>C | p.Thr364Pro | p.T364P | Q765P7 | protein_coding | tolerated(0.05) | possibly_damaging(0.876) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MTSS1L | SNV | Missense_Mutation | c.334N>A | p.Glu112Lys | p.E112K | Q765P7 | protein_coding | deleterious(0.01) | benign(0.281) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| MTSS1L | SNV | Missense_Mutation | novel | c.328C>T | p.Arg110Cys | p.R110C | Q765P7 | protein_coding | deleterious(0) | benign(0.029) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTSS1L | SNV | Missense_Mutation | rs761912285 | c.2186N>A | p.Arg729His | p.R729H | Q765P7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A6QX-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| MTSS1L | SNV | Missense_Mutation | rs770157588 | c.1861N>A | p.Glu621Lys | p.E621K | Q765P7 | protein_coding | tolerated(0.39) | benign(0.102) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| MTSS1L | SNV | Missense_Mutation | novel | c.768N>T | p.Trp256Cys | p.W256C | Q765P7 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTSS1L | SNV | Missense_Mutation | rs770157588 | c.1861N>A | p.Glu621Lys | p.E621K | Q765P7 | protein_coding | tolerated(0.39) | benign(0.102) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MTSS1L | SNV | Missense_Mutation | rs138255587 | c.922N>T | p.Arg308Cys | p.R308C | Q765P7 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MTSS1L | SNV | Missense_Mutation | c.1229N>T | p.Ala410Val | p.A410V | Q765P7 | protein_coding | tolerated(0.14) | benign(0.097) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MTSS1L | SNV | Missense_Mutation | rs149700961 | c.1330N>A | p.Ala444Thr | p.A444T | Q765P7 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |